BucholzS, MorrowAF, ColemanPL. Atypical antipsychotic-induced diabetes mellitus: An update on epidemiology and postulated mechanisms. Intern Med J, 38:602–606. 2008.
2.
GillesM, WilkeA, KopfD, NonellA, LehnerH, DeuschleM. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: Implications for atypical antipsychotics. Psychosom Med, 67:748–751. 2005.
3.
HouseknechtK, RobertsonAS, JohnsonDE, RollemaH. Diabetogenic effects of some atypical antipsychotics: Rapid whole body insulin resistance following a single dose. Diabetologia, 45,Suppl 1:A212. 2005.
4.
JinH, MeyerJM, JesteDV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases. Ann Clin Psychiatry, 14:59–64. 2002.
5.
NewcomerJW, HauntDW, FucetolaR, MelsonAK, SchweigerJA, CooperBP, SelkeG. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry, 59:337–345. 2002.
6.
NewcomerJW, HauptDW. In review: The metabolic effects of antipsychotic medications. Can J Psychiatry, 51:480–491. 2006.
7.
ReavenG, SyndromeX. 10 years after. Drugs, 58,Suppl 1:19–2075–821999.
8.
RyanMC, CollinsP, ThakoreJH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. Am J Psychiatry, 160:284–289. 2003.
